Niedźwiedź Anna, Kawa Miłosz, Pius-Sadowska Ewa, Kuligowska Agnieszka, Ziontkowska Alicja, Wrzałek Dawid, Parczewski Miłosz, Safranow Krzysztof, Kozłowski Krzysztof, Machaliński Bogusław, Machalińska Anna
Department of General Pathology, Pomeranian Medical University, Al. Powstańców Wielkopolskich 72, 70-111 Szczecin, Poland.
First Department of Ophthalmology, Pomeranian Medical University, Al. Powstańców Wielkopolskich 72, 70-111 Szczecin, Poland.
J Clin Med. 2022 May 8;11(9):2647. doi: 10.3390/jcm11092647.
Background: This study investigated the presence and duration of ophthalmic symptoms in the early phase of COVID-19 to assess the corresponding local immune response on the ocular surface. Methods: The study included data from 180 COVID-19 patients and 160 age-matched healthy controls. The main finding was the occurrence of ophthalmological manifestations at the time of admission to the hospital and during the preceding 7 days. Tear film concentrations of TNF-α, IL-1b, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12 p70, GM-CSF, and IFN-γ were determined by a magnetic bead assay. Results: Among the COVID-19 patients, 12.64% had at least one ocular symptom at the time of admission, and 24.14% had symptoms within the preceding 7 days (p < 0.001 vs. controls). We found that the COVID-19 patients complained more frequently about eye tearing (p = 0.04) and eye pain (p = 0.01) than controls. A multivariate analysis of the patients and controls adjusted for age and sex revealed that COVID-19 was an independent factor associated with higher VEGF and IL-10 tear film concentrations (β = +0.13, p = 0.047 and β = +0.34, p < 0.001, respectively) and lower IL-1β, IL-8, and GM-CSF levels (β = −0.25, p < 0.001; β = −0.18, p = 0.004; and β = −0.82, p = 0.0 respectively). Conclusions: SARS-CoV-2 does not attract a strong local response of the conjunctival immune system; therefore, ophthalmic symptoms may not constitute a substantial element in the clinical picture of novel COVID-19 infection.
本研究调查了新型冠状病毒肺炎(COVID-19)早期眼部症状的存在情况及持续时间,以评估眼表相应的局部免疫反应。方法:该研究纳入了180例COVID-19患者和160例年龄匹配的健康对照的数据。主要发现为入院时及入院前7天内出现的眼科表现。采用磁珠法测定泪膜中肿瘤坏死因子-α(TNF-α)、白细胞介素-1β(IL-1β)、白细胞介素-2(IL-2)、白细胞介素-4(IL-4)、白细胞介素-5(IL-5)、白细胞介素-6(IL-6)、白细胞介素-8(IL-8)、白细胞介素-10(IL-10)、白细胞介素-12 p70、粒细胞-巨噬细胞集落刺激因子(GM-CSF)和干扰素-γ(IFN-γ)的浓度。结果:在COVID-19患者中,12.64%在入院时有至少一种眼部症状,24.14%在入院前7天内出现症状(与对照组相比,p < 0.001)。我们发现,COVID-19患者比对照组更频繁地抱怨流泪(p = 0.04)和眼痛(p = 0.01)。对患者和对照组进行年龄和性别校正后的多因素分析显示,COVID-19是与泪膜中血管内皮生长因子(VEGF)和IL-10浓度升高相关的独立因素(β = +0.13,p = 0.047;β = +0.34,p < 0.001),也是与IL-1β、IL-8和GM-CSF水平降低相关的独立因素(β = -0.25,p < 0.001;β = -0.18,p = 0.004;β = -0.82,p = 0.0)。结论:严重急性呼吸综合征冠状病毒2(SARS-CoV-2)不会引起结膜免疫系统强烈的局部反应;因此,眼部症状可能不是新型COVID-19感染临床表现的重要组成部分。